Elizabeth Naldi-Jacob

Bio:

Elizabeth Naldi-Jacob is Vice President and responsible for all BD&L HQ transactions and corporate development. Her deal remit includes all therapeutic areas and different deal types such as license, partnership, M&A, out-license, clinical collaboration, among others. She has been at Merck for ten years and has always served different roles within the business development organization. 

Elizabeth has successfully executed many deals at Merck including our collaborations with Astra Zeneca and Eisai, the recent acquisitions of Verona and Cidara, as well as the acquisitions of Prometheus, Harpoon, Arqule, VelosBio, and Imago.

Prior to Merck, Elizabeth was at Pfizer for five years as the Head of Financial Evaluation and Strategy within Pfizer’s business development organization. Prior to her career in industry, Elizabeth was an equity analyst on Wall Street covering small to mid-cap biotechnology companies and prior to that she was a management healthcare consultant at a boutique healthcare consulting firm.